Overview

Detailed Summary

Auro Laboratories Ltd specializes in the manufacturing of generic Active Pharmaceutical Ingredients (APIs), with a primary focus on anti-diabetic medications like Metformin HCL.
The company is serving international markets, exporting a significant portion of its production to regions such as South East Asia, the Middle East, and Europe.
With a current capacity of 1800 MTPA for Metformin HCL, Auro Laboratories plans to double this capacity, signaling a strong growth trajectory.
The company's manufacturing facilities are ISO 9001:2000 and WHO-cGMP certified, which reinforces their commitment to high-quality production standards.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 151 Cr
Volatility: Low Risk
P/E Ratio: 87.7
Industry P/E: 33.2
PEG Ratio: —
P/B Ratio: 3.5
52W High: 317.00
52W Low: 159.00

Sales CAGR

1Y: -63.83%
3Y: -27.48%
5Y: -15.03%
10Y: -4.53%

Profit CAGR

1Y: -76.38%
3Y: -13.54%
5Y: -14.63%
10Y: 8.51%

ROE

TTM: 4.47%
3Y: 10.13%
5Y: 12.33%
10Y: 14.36%

ROCE

TTM: 7.31%
3Y: 10.33%
5Y: 13.89%
10Y: 16.54%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
NATCAPSUQ		153.00	162 Cr	-8.45	0.71	0.00	-4.87	-1.11	-4.56
AUROLAB		268.00	152 Cr	88.18	3.53	0.00	4.47	7.31	1.55
CORALAB		411.25	150 Cr	10.75	0.71	0.00	8.14	10.97	6.01
PANCHSHEEL		104.25	150 Cr	12.18	1.08	0.70	8.89	11.28	7.21
GUJINJEC		93.10	148 Cr	592.88	14.58	0.00	4.19	5.58	2.14
LACTOSE		86.40	144 Cr	29.75	2.30	0.00	7.24	10.49	3.50
ALPA		70.70	141 Cr	12.11	0.77	0.00	10.18	12.57	4.91
Median: 7 Co.	—	104.25	150 Cr	12.18	1.08	0.00	7.24	10.49	3.50

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2024	Jun 2025	Sep 2025
Sales	3.10	2.77	8.84
Expenses	2.38	2.75	6.48
Operating Profit	0.72	0.02	2.36
OPM %	23.23	0.72	26.70
Other Income	0.31	0.42	0.98
Interest	0.28	0.28	0.96
Depreciation	0.27	0.27	0.65
Profit Before Tax	0.48	-0.11	1.72
Tax %	25.00	0.00	58.14
Net Profit	0.36	-0.11	0.72
EPS in Rs	0.57	-0.17	1.15

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	37	41	47	44	54	51	53	54	19	16
Expenses	31	35	40	38	43	46	49	43	16	14
Operating Profit	5.85	6.23	6.84	6.27	11	4.63	4.39	11	3.40	2.00
OPM %	15.82	15.28	14.61	14.32	20.72	9.09	8.30	19.89	17.54	12.25
Other Income	0.53	0.51	0.96	0.97	0.76	1.09	0.94	1.50	0.66	1.00
Interest	1.07	1.09	0.72	0.58	0.46	0.83	0.81	0.74	1.08	1.11
Depreciation	0.86	0.93	1.01	1.02	1.04	1.02	1.07	1.09	1.10	1.10
Profit Before Tax	2.92	4.73	6.07	5.64	11	3.87	3.45	10	1.88	0.79
Tax %	72.11	25.34	27.51	28.13	31.66	26.57	29.13	24.68	2.24	12.66
Net Profit	0.82	3.53	4.40	4.05	7.18	2.84	2.44	7.79	1.84	0.69
EPS in Rs	4.70	7.59	7.06	6.50	11.54	4.56	3.92	12.41	2.49	4.74
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23
Reserves	2.35	3.18	6.75	11	15	22	25	28	36	37
Borrowings	13	4.95	9.20	8.09	3.16	3.05	14	6.41	26	43
Other Liabilities	4.48	12	8.23	7.96	7.69	10	9.66	15	18	13
Total Liabilities	26	27	30	33	32	42	55	56	86	99
Fixed Assets	9.13	13	13	15	14	14	14	13	22	21
CWIP	3.33	0.23	1.07	0.12	0.12	0.13	3.68	7.67	33	56
Investments	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Other Assets	13	14	16	19	18	28	38	36	31	22
Total Assets	26	27	30	33	32	42	55	56	86	99

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	7.88	6.49	6.05	6.87	9.30	13	-6.59	3.28	19	5.75
Cash from Investing Activity	-2.44	-2.20	-3.04	-3.19	-2.21	-3.51	-5.34	-5.08	-39	-24
Cash from Financing Activity	-5.34	-3.81	-1.77	-1.83	-5.52	-0.46	9.79	-8.18	19	18
Net Cash Flow	0.09	0.47	1.24	1.86	1.58	8.85	-2.14	-9.98	-0.77	-1.02

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	52.09%	52.09%	52.09%	52.15%	52.15%	52.15%	52.15%	52.18%	52.18%	52.18%	52.18%	52.18%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Public	47.90%	47.90%	47.90%	47.84%	47.84%	47.84%	47.84%	47.82%	47.82%	47.82%	47.82%	47.82%
Total Shareholders	10,501	10,272	9,905	9,441	9,335	9,266	9,265	9,102	8,916	8,860	8,640	8,405

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Auro Laboratories Ltd

Auro Laboratories Ltd (AUROLAB) is currently trading at 242.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Auro Laboratories Ltd specializes in the manufacturing of generic Active Pharmaceutical Ingredients (APIs), with a primary focus on anti-diabetic medications like Metformin HCL. The company is serving international markets, exporting a significant portion of its production to regions such as South East Asia, the Middle East, and Europe. With a current capacity of 1800 MTPA for Metformin HCL, Auro Laboratories plans to double this capacity, signaling a strong growth trajectory. The company's manufacturing facilities are ISO 9001:2000 and WHO-cGMP certified, which reinforces their commitment to high-quality production standards.

Over the past 52 weeks, Auro Laboratories Ltd has traded between a low of ₹159.00 and a high of ₹317.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Auro Laboratories Ltd has a market capitalization of approximately 151.67. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Auro Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 88.18 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 151.67 Cr, Auro Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Auro Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Auro Laboratories Ltd is 88.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Auro Laboratories Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Standalone Profit Loss (in ₹ Crores)

Standalone Balance Sheet (in ₹ Crores)

Standalone Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock more with professional

Projection

Documents

Actions

Announcements

AI Mode

Ask AI

Frequently Asked Questions about Auro Laboratories Ltd

What is Auro Laboratories Ltd share price today?

What does Auro Laboratories Ltd do?

What is the 52-week high and low of Auro Laboratories Ltd?

What is the market capitalization of Auro Laboratories Ltd?

Should I consider investing in Auro Laboratories Ltd stock?

Is Auro Laboratories Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Auro Laboratories Ltd belong to and why does it matter?

What is the PE ratio of Auro Laboratories Ltd?

Investor’s Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Technicals

Forecasts

Projection

Announcements

Frequently Asked Questions about Auro Laboratories Ltd

What is Auro Laboratories Ltd share price today?

What does Auro Laboratories Ltd do?

What is the 52-week high and low of Auro Laboratories Ltd?

What is the market capitalization of Auro Laboratories Ltd?

Should I consider investing in Auro Laboratories Ltd stock?

Is Auro Laboratories Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Auro Laboratories Ltd belong to and why does it matter?

What is the PE ratio of Auro Laboratories Ltd?

Oscillators

Bullish

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Peers

Price Chart Comparison

Overview

Financial Ratios

Investment Checklist